Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
VTAK (NYSE American: VTAK) completed acquisition of the remaining 80.02% equity interest in Fly Flyte, making Flyte a wholly owned subsidiary and consolidating a revenue-generating, asset-backed regional aviation platform.
Flyte operates under FAA 14 CFR Part 135 using certified Cirrus Vision Jets, providing immediate cash flow, tangible aircraft and infrastructure, and consolidated revenues going forward.
Catheter Precision (NYSE American: VTAK) said its LockeT suture retention device will be featured in live procedural cases at the International Symposium of Left Atrial Appendage (ISLAA) 2026, held March 5–6, 2026, in Los Angeles.
Company representatives will provide hands-on demonstrations for electrophysiology fellows and highlight LockeT benefits including potential cost reduction and same-day discharge.
Catheter Precision (NYSE American: VTAK) announced a definitive agreement to sell its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer on Feb 19, 2026.
Transaction delivers an upfront cash payment of $15,000, a 5% equity stake in the buyer with anti-dilution protection tied to up to $5 million additional equity, and a 10-year royalty on net sales starting at 1.5% and rising to 3% for quarters above $5 million. Company says proceeds will strengthen the balance sheet and sharpen focus on electrophysiology growth.
VTAK (NYSE American: VTAK) acquired a 19.98% strategic minority stake in Fly Flyte, Inc. on Feb. 17, 2026, gaining immediate exposure to a revenue-generating, FAA Part 135 certified regional operator using AI-enabled operations and a fleet of Cirrus Vision Jets.
The investment preserves Flyte control, targets scalable fleet expansion, and provides optionality for increased ownership or future monetization while aligning VTAK with short-haul regional mobility ahead of potential eVTOL commercialization.
Catheter Precision (NYSE: VTAK) agreed to terminate its at-the-market equity offering and completed a strategic institutional financing for up to $36.5 million to accelerate growth. The company converted approximately $9 million of short and long-term liabilities into equity and extended note maturities to two and three years, strengthening liquidity and aligning with long-term investors.
The company said no future equity lines or forward-priced agreements are anticipated; additional transaction details are available in its Form 8-K filings.
Catheter Precision (NYSE American: VTAK) announced that its LockeT suture retention device will be featured in live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference.
The event runs February 11–13, 2026 at the Hyatt Regency La Jolla at Aventine in San Diego, and inclusion in live cases highlights LockeT's role in workflow efficiency and patient recovery after venous catheter access, according to the company.
Catheter Precision (NYSE American: VTAK) announced expanded hospital evaluations and approvals for its LockeT suture retention device and reports its highest recorded January revenue. The company highlighted new U.S. high-volume center evaluations, international market entries including CE Mark activity, and an expected strong Q1 2026 adoption driven by workflow and cost benefits.
Management named several hospitals undergoing evaluations and cited faster staff onboarding, same-day discharge potential, and continued European penetration as adoption drivers.
Catheter Precision (NYSE/American: VTAK) announced receipt of its first LockeT purchase order in Germany from Universitätsklinikum Frankfurt on January 22, 2026. The order marks LockeT's official entry into the German market and installs the company's suture retention device designed to improve workflow after venous catheter access while remaining cost effective. Catheter Precision cited Germany as the largest healthcare market in Europe and referenced a $900 million German electrophysiology devices market size for 2024. The Frankfurt university hospital will act as a reference site as the company scales operations across Germany and broader Europe.
Catheter Precision (NYSE American: VTAK) received a VIVO purchase order from University Clinical Center Ljubljana, a leading public hospital in Slovenia, expanding the company’s global commercial footprint to 15 countries. The company said the order and recent entries validate VIVO and LockeT adoption by physicians and follow a year of growth driven by distribution partnerships and ongoing navigation of international regulatory processes as it pursues further expansion in 2026.
Catheter Precision (NYSE:VTAK) announced on Dec 18, 2025 the first purchase order and a multi‑year commitment for its LockeT device at Mater Private Hospital in Dublin, Ireland. Mater Private is described as Ireland's largest electrophysiology center, performing over 1,000 EP procedures annually. The company said LockeT was rapidly adopted during onboarding, with 52 staff trained in two days, and that a European key opinion leader helped introduce the device. The agreement represents an initial commercial expansion into an eighth European country following CE mark receipt and supports the company's international adoption strategy.